A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-01-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The trial is planned as a multicentric, randomized, prospective, open study in accordance with a 1/1 plan, on parallel groups and 2 arms of treatment. A total of 200 patients with chronic renal insufficiency, included in the French national waiting list of the Establishment Français des Greffes \[French Transplants Institution\] and receiving a first renal transplant will be included, after signed agreement, in this study. All the patients will receive organs taken from brain-dead subjects. The patients will be given immunosuppressant treatment based on rabbit anti-T lymphocyte serum, CellCeptÒ and NeoralÒ cyclosporin. One group of 100 randomised patients will be given standard corticosteroid therapy as well during the first six months following the transplant. This group will be compared with a second group of 100 randomised patients who will be given a single dose of corticosteroids. The main aim of this study is to evaluate the number of acute rejection episodes in patients given a first renal transplant and subjected to an immunosuppressant protocol not containing corticosteroids. The hypothesis which is proposed is that, in the absence of corticosteroids and/or calcineurin inhibitors (i.e. cyclosporin and tacrolimus), antilymphocyte serum results in a certain state of "tolerance" in respect of the allograft. The second objective concerns the beneficial effect which the absence of corticosteroids may have on short- and long-term postoperative morbidity and mortality. One may in fact assume that the absence of corticosteroids will result in an extension of the transplant patient's life expectancy as a result of the reduction in cardiovascular complications. Cardiovascular complications are the most frequent cause of death after a renal transplant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients

NCT00213590

Kidney Transplantation Primary Prevention Kidney Failure

COMPLETED PHASE3

Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,

NCT00239057

Maintenance Renal Transplantation

COMPLETED PHASE3

Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors

NCT00456235

Liver Transplantation

COMPLETED PHASE4

Calcineurin Free Immunosuppression in Renal Transplant Recipients

NCT00812123

Kidney Transplantation Chronic Kidney Disease

COMPLETED PHASE4

Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients

NCT00199667

Kidney Transplant Recipients

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.

Intervention Type DRUG

Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient who is a candidate for a first cadaver renal transplantation and included on the national list of the Etablissement Français des Greffes
* Man or woman aged between 18 and 65 years
* Women of reproductive age must agree to use a reliable contraceptive method throughout the first year of the study
* Donor aged between 18 and 65 years
* Patient who has been given full information about the study and who has given his written informed consent to take part in it.

Exclusion Criteria

* Women who are pregnant or breast-feeding
* Patient with an immunological risk considered high and defined as a percentage of anti-HLA antibodies of ³20% (previous or recent determination of T lymphocytes)
* Patient with a history of allergy to rabbit proteins
* Cold ischaemia time of more than 36 hours
* Patient allergic to macrolide antibiotics, to tacrolimus or to MMF
* Patient on immunosuppressant treatment before transplantation
* Patient suffering from a malignant neoplasm or with a history of malignant neoplasia, with the exception of treated baso- or spinocellular cancers
* Patient waiting for another transplant in addition to the kidney
* Patient who has already received an organ or tissue graft
* Leukocyte count \<2000/mm3 and/or platelet count \<50 000/mm3
* Patient suffering from focal glomerulonephritis

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No